Topiramate ER Prior Authorization with Quantity Limit Program Summary
Customize your policy alerts
Sign up for all prime_therapeutics policy alerts
Know when prime_therapeutics releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and quantity limits for Trokendi XR and Qudexy XR extended-release topiramate capsules for Boeing commercial members. Coverage requires qualifying clinical criteria, absence of FDA-labeled contraindications, and compliance with the applicable 30-day quantity limit unless an approved exception applies.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.